University of Groningen
Characteristics of aggressive B-cell lymphoma Nijland, Marcel
DOI:
10.33612/diss.97523846
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Nijland, M. (2019). Characteristics of aggressive B-cell lymphoma. University of Groningen. https://doi.org/10.33612/diss.97523846
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
1. Proteomic analysis should not be overlooked in diffuse large B-cell lymphoma, since it can identify cellular pathways and targets for therapy not readily
identified through mutational- and gene expression analysis (this thesis). 2. The negative predictive value of MYC-immunohistochemistry for detecting
MYC rearrangements in transformed follicular lymphoma is excellent. However, the positive predictive value is limited indicating alternative mechanisms of MYC upregulation (this thesis).
3. In addition to loss of human leukocyte antigens, co-stimulatory- and cell adhesion molecules, disrupted antigen processing through loss of HLA-DM contributes to immune escape in diffuse large B-cell lymphoma (this thesis). 4. The occurrence of late relapses, presence of MYC rearrangements and
relapses in the central nervous system should be taken into account when exploring de-escalation studies in stage 1 diffuse large B-cell lymphoma (this thesis).
5. Since the availability of pathological specimens suitable for mutational analysis is insufficient, we should focus on bio banking of sequential liquid biopsies to study the mutational evolution of diffuse large B-cell lymphoma (this thesis).
6. Metabolic active diffuse large B-cell lymphoma is susceptible to necrosis as visualized by 18F-FDG PET irrespective of MYC status and might identify patients at increased risk of therapy failure (this thesis).
7. While we have a better understanding of the pathobiology of lymphomas, we are making the same mistake as 30 years ago: just because aggressive lymphomas have a poor outcome, more chemotherapy is most likely not the answer to more cure (Bartlett et al. JCO 2019).
8. Price agreements between the government and pharmaceutical companies regarding new medication should be made publicly available to keep social support and to facilitate the debate about healthcare costs.
9. Social media have crippled the debate in modern democracies. 10. When building our homes, we should not destroy the world of future
